BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 30, 2009
 |  BioCentury  |  Product Development

Still pursuing PPAR

Dara BioSciences Inc. has decided it's still worth developing PPAR agonists, having announced that it plans to start Phase I testing next quarter of its DB959 for Type II diabetes. The company is banking on preclinical data that suggest the compound will not have the cardiovascular side effects of other PPARs like Avandia rosiglitazone from GlaxoSmithKline plc.

In 2007, Avandia received a black box warning against use in patients with heart failure. Avandia is a thiazolidinedione (TZD) that agonizes peroxisome proliferation activated receptor (PPAR) gamma. Last year, FDA issued guidance that will require companies to conduct larger trials to rule out some level of cardiovascular risks for diabetes therapeutics prior to market approval, even if no safety signal has been detected (see BioCentury, July 14, 2008).

DB959...

Read the full 640 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >